Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 7kWORD 21k
24 August 2017
Answer given by Mr Moedas on behalf of the Commission
Question reference: E-004841/2017

Diabetes research has been a priority for the Commission for many years. Most recently, Horizon 2020, the EU Framework Programme for Research and Innovation (2014-2020)(1), has allocated over EUR 286.5 million to 160 projects in this area. Their aim is to gain a better understanding of the very complex pathophysiology of diabetes and its complications and to deliver personalised health and care(2).

Regarding complications of diabetes affecting the eye, the EU is supporting nine projects with an overall budget of EUR 11.7 million addressing retinopathy and age-related macular degeneration. These projects cover the whole healthcare continuum from aetiology to diagnosis and treatment, to public health and prevention(3),(4),(5),(6),(7),(8),(9),(10),(11).

Horizon 2020 will provide further opportunities for funding research on diabetes through the remaining calls for proposals. Information regarding these opportunities will be made available on the Research and Innovation Participant Portal(12).

(2)PHC-01-2014: Understanding health, ageing and disease: determinants, risk factors and pathways PHC-02-2015: Understanding disease: systems medicine

Legal notice